Event Captivated Today, October 11, 2018
CORALVILLE, Iowa, Oct. 11, 2018 (GLOBE NEWSWIRE) — KemPharm, Inc. (NASDAQ:KMPH), a specialty biologic aggregation focused on the analysis and development of proprietary prodrugs, today provided highlights from its broker accident featuring a altercation with key assessment leaders (KOLs) and prescribing physicians in the acreage of Attention Deficit Hyperactivity Disorder (ADHD). The accident was captivated in New York, NY, on Thursday, October 11, 2018.
The KemPharm ADHD Broker Accident was organized to accommodate investors with a absolute analysis of the dynamics influencing the ADHD analysis landscape, including accepted challenges and unmet medical needs, as able-bodied as an overview of KemPharm’s ADHD prodrug portfolio, which is accent by its two beforehand investigational prodrug candidates for alleviative ADHD, KP415 and KP484.
Keynote speakers included Ann Childress, MD, President of the Center for Psychiatry & Behavioral Medicine in Las Vegas and Adjunct Faculty Member at the University of Nevada School of Medicine; Matthew Brams, MD, Medical Director and Principal, Bayou City Research, and Analytic Associate Professor of Psychiatry at the Baylor College of Medicine; and Timothy E. Wilens, MD, Chief, Division of Child and Adolescent Psychiatry and Co-Director, Center for Addiction Medicine at the Massachusetts General Hospital, and Associate Professor of Psychiatry at Harvard Medical School in Boston.
“We are actual accustomed to accept had the befalling to conduct an ADHD Broker Accident featuring such an admired console of experts in ADHD treatment,” said Travis Mickle, Ph.D., President and Chief Executive Officer of KemPharm. “As we beforehand KP415 appear a aboriginal division 2019 New Drug Application (NDA), we are always reminded of the countless dynamics impacting the ADHD amplitude and the admiration amid prescribers and patients for ameliorative options that bigger abode key unmet medical needs, including aboriginal access of action, continuance of analysis and lower corruption potential. On account of KemPharm, I would like to alone acknowledge Drs. Childress, Brams and Wilens for discussing these important opportunities and area next-generation ADHD therapies, such as KP415 and KP484, could advice to advance the lives of ADHD patients and their caregivers.”
The abounding webcast and presentation slides from the KOL Broker Accident can be accessed via the Broker Relations area beneath “Events & Presentations” on the KemPharm’s website at http://investors.kempharm.com.
The afterward is a epitomize of key presentations from the event:
ADHD Analysis Mural and Using the Laboratory Classroom to Determine Drug EffectsLed by Ann Childress, MD, the aboriginal presentation provided a analysis of the ADHD accommodating and analysis landscape, including key allowances and drawbacks of accepted ADHD medications and abeyant opportunities for advance as developers seek to accompany new articles to market. Additionally, Dr. Childress focused on the architecture and beheading of an ADHD classroom-style analytic abstraction and measures that are acclimated for free efficacy. Included in Dr. Childress’ presentation was a altercation of the SKAMP and PERMP tests and the abstracts that anniversary is advised to provide, as able-bodied as examples and impressions from the KP415.E01 ability study.
Prescribing ADHD Medications in a Large Outpatient Practice: The Good, The Bad, and the UglyIn the aing presentation, Matthew Brams, MD, discussed in detail the accepted ADHD analysis bazaar and the advantages and disadvantages of all-encompassing and branded medications. Importantly, Dr. Brams accent key unmet needs that he believes charge be addressed by next-generation ADHD articles in adjustment for those articles to succeed. Unmet medical needs accommodate faster onset, best duration, bigger tolerability and once-daily dosing.
Nonmedical Use of Prescription StimulantsIn the final KOL presentation, Timothy E. Wilens, MD, discussed the prevalence of analeptic misuse, decidedly the corruption of ADHD medications by college-age individuals. In his remarks, Dr. Wilens acclaimed that amphetamines are the best accepted analeptic aished and that the articulate and intranasal routes are adopted by misusers, highlighting the charge for next-generation ADHD medications that abate the abeyant of abuse.
KemPharm – ADHD Prodrug Portfolio and Corporate UpdateConcluding the ADHD Broker Event, Travis Mickle, Ph.D., advised the latest developments and advancing milestones involving KP415 and KP484, KemPharm’s co-lead analytic development candidates for the analysis of ADHD. Dr. Mickle re-affirmed that KemPharm expects to book the NDA for KP415 in the aboriginal division of 2019, while the NDA acquiescence for KP484 is accepted to chase after in 2019. Additionally, Dr. Mickle discussed the advancing cardinal partnering discussions involving KP415 and KP484 and provided an amend on the afresh completed $25 actor follow-on offering.
KemPharm is a specialty biologic aggregation focused on the analysis and development of proprietary prodrugs to amusement austere medical altitude through its proprietary LATTM (Ligand Activated Therapy) belvedere technology. KemPharm utilizes its proprietary LAT belvedere technology to accomplish bigger prodrug versions of FDA-approved drugs in the aerial charge areas of ADHD, affliction and added axial afraid arrangement disorders. KemPharm’s co-lead analytic development candidates are KP415 and KP484, both based on a prodrug of d-methylphenidate, but with differing extended-release/effect profiles for the analysis of ADHD. In addition, KemPharm has accustomed FDA approval for APADAZ®, an immediate-release aggregate artefact absolute benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For added advice on KemPharm and its activity of prodrug artefact candidates appointment www.kempharm.com or affix with us on Twitter, LinkedIn, Facebook and YouTube.
Caution Apropos Forward Looking Statements:This columnist absolution may accommodate advanced statements fabricated in assurance aloft the safe anchorage accoutrement of Area 27A of the Securities Act of 1933, as amended, and Area 21E of the Securities Exchange Act of 1934, as amended. Advanced statements accommodate all statements that do not chronicle alone to actual or accepted facts, and can be articular by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the abrogating versions of those words or added commensurable words. Advanced statements are not guarantees of approaching accomplishments or performance. These advanced statements are based on advice currently accessible to KemPharm and its accepted affairs or expectations and are accountable to a cardinal of uncertainties and risks that could decidedly affect accepted plans. Risks apropos KemPharm’s business are declared in detail in KemPharm’s Quarterly Report on Form 10-Q for the division concluded June 30, 2018, filed with the Securities and Exchange Commission (SEC) on August 10, 2018, and KemPharm’s added Periodic and Accepted Reports filed with the SEC. KemPharm is beneath no obligation to (and especially disclaims any such obligation to) amend or adapt its advanced statements, whether as a aftereffect of new information, approaching contest or otherwise.
Investor/Media Contacts: Jason Rando / Joshua Drumm, Ph.D.Tiberend Cardinal Advisors, Inc.212-375-2665 / [email protected]@tiberend.com
10 Ingenious Ways You Can Do With Medical Treatment Release Form For Child | Medical Treatment Release Form For Child – medical treatment release form for child
| Welcome to be able to my blog, in this particular period I’m going to provide you with regarding medical treatment release form for child